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Semaphorin	3E	(Sema3E)	is	a	secreted	molecule	implicated	in	axonal	path	finding	and	inhibition	of	devel-
opmental	and	postischemic	angiogenesis.	Sema3E	is	also	highly	expressed	in	metastatic	cancer	cells,	but	its	
mechanistic	role	in	tumor	progression	was	not	understood.	Here	we	show	that	expression	of	Sema3E	and	its	
receptor	Plexin	D1	correlates	with	the	metastatic	progression	of	human	tumors.	Consistent	with	the	clinical	
data,	knocking	down	endogenous	expression	of	either	Sema3E	or	Plexin	D1	in	human	metastatic	carcino-
ma	cells	hampered	their	metastatic	potential	when	injected	into	mice,	while	tumor	growth	was	not	markedly	
affected.	Conversely,	overexpression	of	exogenous	Sema3E	in	cancer	cells	increased	their	invasiveness,	tran-
sendothelial	migration,	and	metastatic	spreading,	although	it	inhibited	tumor	vessel	formation,	resulting	in	
reduced	tumor	growth	in	mice.	The	proinvasive	and	metastatic	activity	of	Sema3E	in	tumor	cells	was	depen-
dent	on	transactivation	of	the	Plexin	D1–associated	ErbB2/Neu	oncogenic	kinase.	In	sum,	Sema3E–Plexin	D1	
signaling	in	cancer	cells	is	crucially	implicated	in	their	metastatic	behavior	and	may	therefore	be	a	promising	
target	for	strategies	aimed	at	blocking	tumor	metastasis.
Introduction
Semaphorins are secreted and membrane-bound signals, original-
ly implicated in the control of axonal wiring (1). They comprise a 
wide protein family and are involved in a range of functions, from 
tissue morphogenesis to the immune response, to cancer progres-
sion. High-affinity semaphorin receptors are found in the fami-
lies of the plexins and of the neuropilins (2). The relevance of the 
small cytoplasmic domain of neuropilins in semaphorin signaling 
is unclear; however, the intracellular domain of plexins has been 
characterized for controlling R-Ras and RhoA activity and hence 
negatively regulates integrin-mediated adhesion and cell migra-
tion (1, 3). In addition, other molecules can interact with sema-
phorins or semaphorin receptors on the cell surface, featuring a 
complex scenario of multiple potential signaling pathways. In par-
ticular, tyrosine kinase receptors may become activated in response 
to semaphorins (4–7). This often leads to an apparent biological 
paradox whenever a semaphorin, in addition to mediating inhibi-
tory signals (e.g., cell repulsion, inhibition of cell migration, etc.), 
can furthermore promote cell migration and invasive growth by 
activating tyrosine kinases in a cell-specific manner (8).
The role of semaphorin signalling in tumor progression is cur-
rently under close scrutiny. It is known that cancer cells release 
semaphorins regulating their own behavior as well as that of cells 
in the tumor microenvironment, such as endothelial cells and 
recruited leukocytes (see refs. 9 and 10 for reviews). For example, 
semaphorin 3B (Sema3B), Sema3F, and Sema4D have been shown 
to differently regulate tumor growth, tumor angiogenesis, and 
metastatic progression (11–16). Moreover, based on scattered evi-
dence, semaphorin expression levels might discriminate among 
tumor cells with different metastatic abilities (13, 17, 18). In this 
work, we focused on Sema3E (previously known as semaH), which 
was found to be overexpressed in metastatic tumor cells (17). We 
have previously demonstrated that, like other class 3 semapho-
rins, Sema3E is synthesized as a full-length precursor molecule of 
approximately 87 kDa (p87-Sema3E), which is then subjected to 
proteolytic maturation by furin proprotein-convertases (PPCs), 
yielding a smaller fragment of approximately 61 kDa, referred to 
as p61. We have further shown that this proteolytic fragment pro-
motes lung colonization of tumor cells injected in the circulation 
(19), but the implicated mechanisms remained unclear.
The high-affinity functional receptor of Sema3E is Plexin D1 
and not any of the neuropilins (20). Genetic evidence showed that 
Sema3E–Plexin D1 signaling is required in developmental angio-
genesis (20, 21). Moreover, recent evidence indicates that Sema3E 
is implicated in regulating postischemic angiogenesis (22). Intrigu-
ingly, while Plexin D1 expression is generally low in normal adult 
tissues, it is elevated in endothelial cells of tumor vessels and in 
cancer cells (23, 24). Like other family members, Plexin D1 is able 
to trigger R-Ras inactivation, leading to axonal and cell repulsion 
in vitro (25). Moreover, it was shown that Sema3E mediates either 
axonal attraction or repulsion in distinct neuronal populations, 
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depending on the coexpression of Neuropilin-1 with Plexin D1 
(26). This suggests that Sema3E can mediate divergent functions 
in different cells, depending on the implicated receptor complexes. 
Intriguingly, according to a recent report, Sema3E could inhibit 
the survival of MDA-MB-435 tumor cells in vitro but not their 
growth in vivo, while the opposite was true for MDA-MB-231 car-
cinoma cells (27); however, the mechanisms involved could not be 
elucidated. In the present work, we show that Sema3E is a dou-
ble-faced signal in cancer development, eliciting 2 mirror effects 
in tumor cells and in the endothelial cells of tumor vessels, and 
further elucidate the implicated signaling pathways. Moreover, we 
show that Sema3E expression in human primary tumors is statis-
tically associated with their metastatic progression and demon-
strate in mouse preclinical models that interfering with Sema3E 
signaling in primary tumors results in a striking reduction of their 
metastatic dissemination.
Results
Sema3E expression correlates with the metastatic potential of human 
tumors. Sema3E was initially identified in mouse metastatic cancer 
cells (17). However, whether the expression of Sema3E or its recep-
tor Plexin D1 in human primary tumors may be correlated with 
the metastatic progression has not been assessed. We analyzed 
gene expression in a wide series of 60 human colon carcinoma 
samples, for which we obtained detailed clinicopathological infor-
mation (including the possible development of metastasis), as well 
as in a separate series of excised liver metastases (Supplemental 
Figure 1A; supplemental material available online with this article; 
doi:10.1172/JCI42118DS1). While the expression of the receptor 
Plexin D1 was clearly detected in all primary tumors, Sema3E lev-
els were above detection threshold in only a fraction of them (inde-
pendently from tumor grade or stages of local invasiveness; data 
not shown). Interestingly, Sema3E was expressed in 88% of the 
cases associated with metastatic disease (M1) and in only 46% of 
the nonmetastatic tumors (M0). This biased distribution was sta-
tistically significant, as confirmed by Fisher’s exact test (P = 0.004). 
Consistently, as shown in Table 1, average Sema3E expression lev-
els were significantly higher in metastatic versus nonmetastatic 
primary tumors (P = 0.002). Moreover, we could invariably detect 
Sema3E expression in 100% of liver metastases from colon carci-
nomas, and average levels of Sema3E and Plexin D1 were signifi-
cantly higher in metastasis compared with primary tumors. Thus, 
Sema3E–Plexin D1 signaling seems to correlate positively with the 
metastatic progression of human colon carcinomas.
Interestingly, a recent immunohistochemistry analysis showed 
that Plexin D1 receptor levels are increased in invasive and meta-
static melanomas, compared with low-grade tumors and benign 
nevi (28). Previous data on Sema3E expression in melanomas were 
controversial; thus, we analyzed a wide series of benign nevi, low-
grade melanomas, and highly invasive and metastatic melanomas, 
by using a polyclonal antibody previously validated for detecting all 
isoforms of Sema3E, including the proteolytically activated frag-
ment p61 (19). We found that Sema3E was expressed in only a frac-
tion of the melanocytes forming benign or dysplastic nevi as well as 
of the melanoma cells of low grade; in contrast, the percentage of 
Sema3E-positive cells increased to almost 100% in invasive and met-
astatic melanomas of Clark levels III and IV (Figure 1). Moreover, 
Sema3E expression at the single cell level seemed to be higher in 
malignant melanomas, compared with nevi. Thus, according to our 
data, also in melanoma progression, Sema3E signaling in primary 
tumors correlates with the potential for metastatic spreading.
Knocking down either Plexin D1 or Sema3E expression in cancer cells 
curtails metastatic spreading. We have demonstrated above that 
Sema3E levels directly correlate with the invasive and metastatic 
phenotype of human tumors of different histotype. We therefore 
investigated whether the genetic knockdown of either Sema3E (or 
its receptor Plexin D1) in validated experimental tumor models 
could affect the metastatic behavior. As shown in Figure 2A, we 
first silenced Plexin D1 expression in human metastatic carcino-
ma cells A549 (expressing endogenous Sema3E) and transplanted 
them in athymic mice to study tumor development and metastatic 
dissemination. Interestingly, Plexin D1–deficient tumors devel-
oped as controls (Figure 2B), suggesting that Plexin D1 expression 
in cancer cells do not have a major role in regulating growth or 
survival. In contrast, the number of lung metastases that spon-
taneously arose from Plexin D1–depleted primary tumors was 
significantly reduced (Figure 2C), indicating a pivotal role of this 
receptor in the invasive-metastatic process.
In order to assess the functional relevance of endogenous 
Sema3E expression in tumor cells, we furthermore generated and 
transplanted in vivo Sema3E-deficient A549 cells (Figure 2, D–F). 
Analogously, we knocked down Sema3E expression in highly meta-
static 4T1 breast carcinoma cells and carried out tumor transplan-
tation experiments in syngenic mice, both subcutaneously and in 
the orthotopic site of mammary fat pad (Figure 2, G–L). Although 
the growth of the subcutaneous and orthotopic tumors was not 
significantly affected upon Sema3E silencing (Figure 2, H and J), 
their spontaneous metastatic dissemination was significantly 
reduced (Figure 2, I and K). Moreover, knocking down the endog-
enous Sema3E expression greatly reduced the metastatic potential 
of tumor cells injected in the systemic circulation (Figure 2L). These 
data were further validated using a second independent shRNA tar-
geting the Sema3E transcript (Supplemental Figure 2, A and B). 
In addition, and consistent with our expression data in human 
tumor samples, we found that the metastatic potential of HCT-116 
colon carcinoma cells was significantly reduced upon Sema3E 
knockdown (Supplemental Figure 2C). Altogether, our results indi-
cate that the expression of both Sema3E and Plexin D1 is crucially 
involved in the metastatic spreading of diverse cancer cells.
Sema3E overexpression inhibits tumor vessel density and tumor growth 
but promotes metastatic spreading. Prompted by the results reported 
above, we questioned whether a gain of Sema3E expression could in 
turn enhance the metastatic potential of tumor cells. Three human 
cancer cell lines (i.e., HCT-116 colon carcinoma, MDA-MB-435 
Table 1
Relative gene expression levels in human colorectal tumors 
and metastases
Gene	 Primary	tumors	 Metastases
	 M0	 M1	
SEMA3E	 0.03 ± 0.01 0.42 ± 0.19A 0.65 ± 0.17B,C
PLXND1	 7.16 ± 1.89 7.47 ± 2.91 20.4 ± 3.15B
Quantitative RT-PCR data are presented as average ± SEM of tran-
scripts per 104 copies β-actin (n = 43 M0 primary tumors, n = 17 M1 
primary tumors, and n = 51 metastases) (see also Supplemental Figure 
1, A–C). M0, nonmetastatic tumors; M1, tumors associated with meta-
static disease. AP < 0.01 versus M0 primary tumors; BP < 0.0001 versus 
primary tumors; CP < 0.01 versus M1 primary tumors.
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melanoma, and A549 lung carcinoma) were therefore transduced 
with lentiviral vectors encoding Sema3E or empty vector (EV) con-
trols. Overexpressing cells contained a small amount of the full-
length Sema3E precursor of approximately 87 kDa (p87-Sema3E) 
as well as a predominant amount of the matured fragment p61 
(Supplemental Figure 3A and data not shown), indicating an effi-
cient spontaneous proteolytic conversion. Notably, p61 was also 
the main species of endogenous Sema3E released by cancer cells 
(including those used for our gene knockdown experiments; see 
Supplemental Figure 3B). Moreover, we found that the p61 frag-
ment was fully competent to bind the receptor Plexin D1 and elicit 
the typical collapsing response (Supplemental Figure 3, C and D). 
For these reasons, in many subsequent experiments, a recombi-
nant form of the matured p61 fragment was also used.
Sema3E overexpression did not elicit morphological changes 
in cancer cells (data not shown), and we did not observe any sig-
nificant difference in viability and proliferation in culture (Sup-
plemental Figure 4A). Sema3E-expressing and control cells were 
then transplanted subcutaneously in nude mice to establish pri-
mary tumors. Remarkably, the elevated expression of Sema3E led 
to a significant reduction in tumor volume and weight in both 
models (Figure 3A and Supplemental Figure 4B). By assessing the 
mitotic index (with Ki-67; Figure 3B) in tumor tissue sections, we 
found that Sema3E expression did not significantly affect tumor 
cell proliferation, consistent with in vitro analysis. However, cel-
lular apoptosis in Sema3E-expressing tumors was increased by 
approximately 2 fold, as revealed by TUNEL (Figure 3C) and fur-
ther confirmed by the detection of the apoptotic markers cleaved 
caspase-9 and lamin B (Figure 3D). Notably, we found that the 
vascular density of Sema3E-expressing tumors was significantly 
reduced (Figure 3E); moreover, Sema3E had significantly induced 
endothelial cell apoptosis (Figure 3F). These data suggested a 
potential paracrine activity in the microenvironment of the sema-
phorin released by tumor cells.
When looking at the metastatic spreading from these primary 
tumors, we found that — despite their reduced size — tumors over-
expressing Sema3E gave rise to a strikingly increased number of 
spontaneous lung metastases (Figure 4A) expressing Sema3E (Sup-
plemental Figure 5A), which indicated a predominant effect of the 
semaphorin to enhance the invasive-metastatic process. Notably, 
tumor xenografts overexpressing full-length processable Sema3E 
mainly contained mature p61 fragments (Supplemental Figure 5B), 
further confirming in vivo an efficient proteolytic conversion of the 
precursor. Moreover, the expression of a recombinant p61 fragment 
in tumors resulted in comparable effects in vivo, as observed with 
wild-type processable Sema3E undergoing spontaneous proteolytic 
conversion (Supplemental Figure 5, C–E, and Figure 4B).
To establish the functional relevance in vivo of Sema3E signal-
ing in cancer cells, as opposed to its potential paracrine activity on 
endothelial cells, we knocked down the expression of the receptor 
Plexin D1 in MDA-MB-435 cells. Plexin D1–silenced cancer cells 
were viable and did not display any morphological change in culture 
(data not shown). Importantly, we found that Plexin D1 knockdown 
in cancer cells did not prevent the inhibitory effect of p61-Sema3E 
on tumor growth (Figure 4C), tumor vessel density (Figure 4D), or 
endothelial cell apoptosis (data not shown), supporting the idea that 
secreted Sema3E acts on the tumor endothelium in a paracrine man-
ner. In contrast, p61-Sema3E overexpression could not induce the 
metastatic behavior of these Plexin D1–deficient cells (Figure 4E). 
Thus, the prometastatic activity of Sema3E is a tumor cell–autono-
mous, Plexin D1–dependent effect, independent from the paracrine 
activity capable of endothelial cells repulsion. These results could 
explain the apparent paradox observed in our experimental tumors 
in vivo and suggested 2 independent functions mediated by p61-
Sema3E in different cell types, via the same receptor, Plexin D1.
Overall, forced overexpression of Sema3E in cancer cells upholds 
a paracrine antiangiogenic effect and leads to reduced tumor 
growth, a functional effect which was not observed with endog-
Figure 1
Elevated Sema3E expression in invasive human melanomas. (A–F) Sema3E expression was detected by immunohistochemistry in a series 
of 58 nevi and melanoma human samples, representing different stages of progression. Micrographs show representative fields of Sema3E-
expressing samples: (A) an intradermal nevus, (B) a dysplastic nevus, (C) a Clark III level malignant melanoma, and (D and E) 2 different Clark IV 
level melanomas. (F) Control staining of a Clark IV melanoma, without including the specific antibody. Scale bar: 40 μm. (G) In the graph, each 
case is represented by a blue bar, indicating the fraction of Sema3E-positive cells in the sample (scored as described in Methods). Black bars 
indicate the mean value for each of 5 groups (intradermal-junctional nevi [nevi], dysplastic nevi/melanomas in situ [dyspl.], and Clark II, Clark III, 
and Clark IV level melanomas).
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Figure 2
Plexin D1 and Sema3E knockdown in tumor cells inhibits the metastatic spreading. (A–C) A549 carcinoma cells were transduced to stably 
express shRNAs targeting Plexin D1 (or unrelated control sequences), and the expression knockdown was verified by Q-PCR (data not 
shown) and (A) Western blotting. Plexin D1–deficient and control cells were then transplanted into nude mice to establish subcutaneous 
tumors. Throughout the graphs, (B, E, H, and J) display the growth of primary tumors and (C, F, I, and K) the number of spontaneous lung 
metastases scored at the end of the experiment. Data are given as average ± SD of 6 mice for each experimental group throughout. (C) 
**P < 0.005. (D–F) A549 cells were transduced to stably express shRNAs targeting Sema3E (or unrelated control sequences), and gene 
knockdown was verified by Q-PCR (data not shown) and (D) Western blotting. **P < 0.003. The expression of a second independent shRNA 
targeting Sema3E yielded similar results (see Supplemental Figure 2, A and B). (G–I) Analogous experiment as above, using Sema3E-depleted 
4T1 cells injected subcutaneously into syngenic Balb/c mice. **P < 0.007. (J and K) The same Sema3E-depleted 4T1 cells as above were 
injected orthotopically in the fat pad of Balb/c mice. Data are given as the average ± SD of 6 mice for each experimental group. **P < 0.003. 
(L) The same Sema3E-deficient 4T1 cells (as in G–K) were directly injected intravenously in Balb/c mice, and the number of lung metastatic 
colonies was evaluated as above. **P < 0.004.
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enous expression levels. On the other hand, both gene knockdown 
and overexpression experiments indicated that the Sema3E-depen-
dent prometastatic effect depends on a distinctive signalling cas-
cade into tumor cells, mediated by the Plexin D1 receptor.
Sema3E-dependent endothelial cell repulsion relies on Rnd2-expression 
and R-Ras inactivation. In an attempt to unravel the mechanisms 
underlying the effects of Sema3E on tumor vessels and metasta-
sis, we performed in vitro experiments analyzing endothelial and 
tumor cells, respectively.
Functional assays in culture demonstrated that Sema3E (and its 
matured fragment p61) was capable of inhibiting the migration 
of HUVECs in a Plexin D1–dependent manner and eliciting their 
repulsion and cellular collapse (Figure 5, A and B, and Supplemen-
tal Figure 6, A and B). Moreover, in a mixed-culture experiment 
reminiscent of the in vivo setting, we found that Sema3E-express-
ing tumor cells could efficiently induce endothelial cell repulsion 
only if the latter contained Plexin D1 (Supplemental Figure 6B).
It was recently shown that cell collapse and axonal repulsion 
mediated by Plexin D1 depend on its intrinsic R-Ras GAP activity 
(25). To investigate the relevance of this pathway in endothelial 
cells treated with Sema3E, we overexpressed a dominant-active 
mutant of R-Ras that cannot be regulated by Plexin D1 (25) and 
found that endothelial cells were no longer sensitive to p61-
dependent inhibition of migration (Figure 5C). Moreover, it was 
reported that the GAP activity of Plexin D1 depends on the asso-
ciation of the small GTPase Rnd2 (25). Notably, we found that 
Rnd2 is abundantly expressed in HUVECs (Supplemental Figure 
6C); moreover, upon knocking down Rnd2 expression, these cells 
became insensitive to Sema3E-mediated inhibition of migration 
(Figure 5D) and cellular collapse (Figure 5E). These data indi-
cate that the inhibitory function of Sema3E in endothelial cells 
is dependent on the R-Ras GAP activity of Plexin D1 and on their 
prominent expression of Rnd2. Altogether, these data are consis-
tent with the reported restrictive role of Sema3E in developmental 
and postischemic angiogenesis (20, 22) and with our in vivo data 
indicating inhibition of tumor vasculature.
p61-Sema3E signaling in tumor cells promotes motility and invasiveness, 
transendothelial migration, and extravasation in vivo. We aimed at elu-
cidating the molecular mechanisms responsible for the prometa-
static activity of p61-Sema3E. As demonstrated above in Figure 4E, 
our experimental evidence indicates that this function crucially 
depends on signaling cascades deployed into the tumor cells, which 
could potentially regulate their intrinsic migratory and invasive/
metastatic behavior. In keeping with this hypothesis, we found that 
different cancer cells were induced to migrate in response to p61-
Sema3E, either provided in the environment (Figure 6A) or consti-
tutively overexpressed in autocrine manner (Figure 6B); moreover, 
this function was dependent on endogenous Plexin D1 receptor 
expression (Figure 6B). Notably, unlike HUVECs, none of the can-
cer cells analyzed underwent the collapsing response upon Sema3E 
treatment (Supplemental Figure 6A and data not shown), possibly 
reflecting their relatively low expression of the required mediator 
Rnd2 (see Supplemental Figure 6C). Moreover, knocking down 
Rnd2 expression did not impair Sema3E-induced cancer cell migra-
tion (Supplemental Figure 10A). Thus, cancer cells and endothelial 
cells respond differently to Sema3E/Plexin D1 signaling.
Further elucidating the mechanisms involved in the prometa-
static activity of p61-Sema3E in tumor cells, we found that it 
promotes the invasion of the ECM (Figure 6C). Moreover, p61 
expression induced ECM degradation spots, colocalizing with 
actin-enriched focal structures (Supplemental Figure 7), resem-
bling adhesive contacts called invadopodia, which are known to 
mediate the localized release of ECM-degrading enzymes (29). 
Notably, ECM degradation and invadopodia are instrumental for 
cancer cells slithering in and out blood vessel walls in order to 
metastasize. To address the potential involvement of p61-Sema3E 
in tumor cell extravasation, we initially exploited a transendothe-
lial migration assay in vitro. We found that p61-expressing tumor 
cells, unlike controls, promptly migrated through a compact 
monolayer of endothelial cells (Figure 6D). Importantly, p61-
induced transendothelial migration was abrogated in cancer cells 
lacking Plexin D1 receptor (Figure 6D).
It is known that a limited fraction of the cells released in 
the circulation by primary tumors forms metastases. Some of 
these cells die soon after entering the blood stream; others get 
entrapped in narrow capillary beds (e.g., in the lungs) and die 
in thrombotic emboli or manage to return in the circulation. A 
minority of circulating cancer cells will manage to extravasate, 
eventually forming metastatic colonies. In order to elucidate in 
vivo the role of Sema3E in tumor cell extravasation, we injected 
intravenously fluorescence-labeled MDA-MB-435 cells express-
ing p61 (or EV-controls) and subsequently sacrificed mice at 
different time points (from 15 minutes to 48 hours after injec-
tion) to quantify metastatic spreading. Initially, as expected, 
tumor cells accumulated in the lungs, independent from their 
expression of p61-Sema3E (Figure 7A) and consistent with the 
mechanical entrapment in the first encountered capillary bed. As 
expected, the number of cancer cells present in the lungs gradu-
ally decreased over time. However, by 1 hour after injection, p61-
Sema3E–expressing cells were found in strikingly greater num-
ber compared with controls. At 48 hours after injection, 10-fold 
more p61-expressing cells were present in the lungs. This is con-
sistent with the fact that p61- expressing cells directly injected 
in the circulation gave origin to a larger number of metastatic 
lung colonies, as scored in long term experiments (Supplemen-
tal Figure 8A). Moreover, similar experiments were performed 
by using Plexin D1–silenced cancer cells. In this case, p61-
Sema3E could not induce the metastatic behavior (Figure 7B), 
thereby confirming that the proinvasive and prometastatic 
activity displayed by p61-Sema3E is dependent on a signaling 
cascade intrinsic to tumor cells.
Furthermore, we used a drug-inducible system to control sema-
phorin expression in tumor cells injected in vivo (see Supplemental 
Methods for details). Two groups of mice received cells in which 
p61-Sema3E expression had been induced before injection; for one 
group drug treatment was maintained until the end of the experi-
ment, whereas for the other group, treatment was stopped 4 days 
after injection (in order to terminate p61 expression after extrava-
sation in lungs had occurred). Other mice received untreated cells, 
and p61 expression began only 4 days after injection. One month 
later, the lungs were analyzed to score the presence of metasta-
ses. We found that p61-Sema3E expression in cancer cells, at the 
time of injection, resulted in a 10-fold increase in the number of 
metastatic colonies compared with that of controls (even if drug-
induced expression was terminated soon after). On the contrary, 
the induction of semaphorin expression after the extravasation 
step only produced a negligible increase in the number of detect-
able lung colonies compared with that of controls (Supplemental 
Figure 8B). These data strongly suggested that p61-Sema3E main-
ly acts by promoting tumor cell extravasation.
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The prometastatic activity of p61-Sema3E is mediated by the transacti-
vation of Plexin D1–associated ErbB2. Other semaphorins, including 
Sema4D and Sema6D, have been shown to elicit cancer cell migra-
tion and invasive growth (4–6). Interestingly, the implicated recep-
tors (i.e., Plexin B1 and Plexin A1) interact with receptor tyrosine 
kinases (RTKs) and trigger their distinctive signal pathways and 
functional outcomes. By analogy, p61-Sema3E could elicit the 
activation of a RTK associated with Plexin D1, putatively respon-
sible for the observed prometastatic effect. We therefore under-
took an unbiased screening approach to search for potential can-
Figure 3
Sema3E overexpression inhibits tumor vessel density and tumor growth. (A) Sema3E-overexpressing and EV-control cancer cells of differ-
ent histotypes were transplanted subcutaneously in nude mice. The growth of primary tumors was followed by external measuring (shown in 
Supplemental Figure 4B). Values in the graph indicate tumor weight at the end of the experiment. Data shown represent the average ± SD of 
6 mice per each experimental condition. *P < 0.01; **P < 0.005. (B) Control (EV) and Sema3E-expressing tumor sections (as indicated) were 
immunostained to detect Ki-67 proliferation marker. The graph indicates the percentage of KI-67–positive cells (average ± SD). (C) Tumor sections 
(as above) were analyzed to reveal apoptotic cells by TUNEL. Data in the graph show the percentage of TUNEL-positive cells (average ± SD). 
***P < 0.001. Two representative fields of HCT-116 tumors are shown. Nuclei were visualized by hematoxylin. Scale bar: 30 μm. (D) Western blot 
analyses, revealing 2 different apoptotic markers in lysates of Sema3E-expressing tumors, i.e., cleaved caspase-9 and the presence of lamin B 
in the cytosolic fraction. (E) Tumor sections were stained with anti-CD31 to reveal endothelial cells (in red). Values in the graph indicate the 
vessel density (average ± SD). **P < 0.005. Scale bar: 40 μm. (F) Apoptotic endothelial cells in tumors were identified by double staining with 
endoglin (red) and activated caspase-3 (green) markers. *P < 0.02. Scale bar: 10 μm.
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didates in a low-density array, designed to simultaneously detect 
the tyrosine phosphorylation of 42 different RTKs in cell lysates. 
Interestingly, we found that ErbB2 phosphorylation was selective-
ly increased in A549 carcinoma cells in response to p61-Sema3E 
(Supplemental Figure 9). ErbB2 is an oncogenic receptor often 
implicated in cancer invasion and metastasis; it has no cognate 
ligand but commonly becomes activated by forming heterodimers 
with other receptors of the same family (such as EGFR or ErbB3) 
(30–32). We have therefore individually analyzed immunopurified 
ErbB2 (Figure 8A) and the homologous ErbB3 and EGFR tyrosine 
kinases (Figure 8B) in cells treated with p61-Sema3E. In addition 
to that of ErbB2, we observed a minor increase in EGFR tyrosine 
phosphorylation induced by p61, while ErbB3 was not affected. 
ErbB2 phosphorylation in response to p61 was further confirmed 
in HeLa (Figure 8C) and MDA-MB-435 cells (data not shown). 
Notably, while p61 cannot bind ErbB2 (data not shown), it elic-
ited ErbB2 phosphorylation in a Plexin D1–dependent manner, as 
demonstrated by receptor knockdown (Figure 8C).
Interestingly, we could copurify Plexin D1 and ErbB2 from 
lysates of overexpressing cells (Figure 8D), suggesting that they can 
form receptor complexes on the cell surface. Moreover, Plexin D1 
became tyrosine phosphorylated in this complex upon p61 stimu-
lation (Figure 8E), and this was impaired by an ErbB2 kinase inhib-
itor but not upon inhibition of the unrelated RTK Met (Figure 8E). 
Finally, and most importantly, we found that the 2 endogenous 
receptors Plexin D1 and ErbB2 associated in a complex in tumor 
cells, upon stimulation with p61-Sema3E (Figure 8F).
We then found that p61-induced migration of cancer cells was 
impaired upon inhibition of ErbB2 catalytic activity (Figure 9A 
and Supplemental Figure 11, A and B). Moreover, p61-expressing 
cells were unable to give rise to lung metastatic colonies upon sys-
temic treatment of recipient mice with ErbB2 inhibitor (Figure 9B). 
Furthermore, by knocking down ErbB2 expression in cancer cells 
with RNAi technology, we could selectively impair p61-Sema3E 
signaling, both in vitro and in vivo. In fact, while ErbB2-depleted 
cells were viable and sensitive to motogenic signals, like hepa-
Figure 4
Sema3E-p61 signaling in cancer cells enhances the metastatic spreading. (A) Superficial metastases in the lungs of mice bearing subcutane-
ous tumor xenografts formed by control or Sema3E-expressing HCT-116, MDA-MB-435, or A549 cells. Data on primary tumors are displayed in 
Figure 3 and Supplemental Figure 4B. The graph indicates average values ± SD of 6 mice per each experimental condition throughout the figure. 
*P < 0.04; **P < 0.005. (B) As above, we scored lung metastases in mice transplanted with MDA-MB-435 cancer cells expressing either process-
able Sema3E (largely converted into p61 in vivo) or the truncated recombinant p61 isoform. Data on primary tumors are shown in Supplemental 
Figure 5, C–E. *P < 0.02; **P < 0.005. (C–E) Plexin D1–deficient MDA-MB-435 cancer cells (or controls), either expressing p61-Sema3E or EV 
(expression analysis is shown on the bottom) were injected subcutaneously in nude mice to form tumor xenografts. (C) Primary tumors carrying 
p61-Sema3E grew significantly less compared with controls and (D) displayed a reduced vessel density, independently from the expression of 
Plexin D1 in cancer cells, thereby suggesting a paracrine activity of the semaphorin in the microenvironment. (E) Conversely, p61 expression 
could not induce the metastatic spreading of tumor cells devoid of Plexin D1. *P < 0.05; ***P < 0.0005.
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tocyte growth factor, they did not respond to p61 in migration 
assays (Figure 9C) or in experimental metastasis assays in vivo 
(Figure 9D). Taken together, these data indicated that ErbB2 plays 
a master role in the invasive-metastatic properties orchestrated by 
p61-Sema3E and its receptor.
ErbB2-mediated signaling is well characterized, and MAPK, PI3K-
AKT, and PLC-γ appear to be the main players (30, 31). Interest-
ingly, MAPK and PLC-γ cascades are typically activated in response 
to EGFR-ErbB2 heterodimers, while the PI3K-AKT pathway is the 
main mediator of ErbB2-ErbB3 complexes. We therefore analyzed 
the individual contribution of these signal transducers in Sema3E-
induced tumor cell migration by applying the selective inhibi-
tors LY294002, PD98059, and U-73122. As shown in Figure 9E, 
MAPK and PLC-γ activation appeared to be required for function, 
while the PI3K-AKT pathway was only marginally implicated. 
Moreover, our analysis of MAPK, AKT, and PLC-γ phosphoryla-
tion in tumor cells treated with Sema3E indicated a major activa-
tion of MAPK and PLC-γ (Supplemental Figure 12). Thus, our data 
suggest that Sema3E/Plexin D1–dependent activation of a signal-
ing cascade downstream to ErbB2 phosphorylation, especially via 
MAPK and PLC-γ activation, is mainly responsible for the observed 
proinvasive and prometastatic function.
Discussion
Semaphorins and their receptors have been implicated in a range 
of functions, including angiogenesis and tumor progression (9, 10). 
In particular, the functional relevance of Sema3E in cancer was 
poorly understood, and the implicated signaling mechanisms had 
Figure 5
Molecular mechanisms of Sema3E-dependent endothelial cell repulsion. (A) The haptotactic migration of HUVECs was analyzed in the presence 
of 7 nM purified Sema3E (or equal concentration of Sema3A, as positive control) in the lower chamber. Migrated cells were stained with crystal 
violet and quantified by absorbance at 595 nm (see Methods for details). The graphs show the average ± SD of at least 2 independent experi-
ments throughout the figure. **P < 0.005. See also Supplemental Figure 6, A and B. (B) Plexin D1 expression was knocked down in HUVECs 
(verified by Q-PCR), and the haptotactic migration of these cells was assayed in Transwell inserts. Both processable wild-type Sema3E (yielding 
a p87/p61 mix) and the recombinant p61-Sema3E fragment (7 nM each) inhibited the migration of controls but not of Plexin D1–deficient cells. 
Migrated cells were quantified by staining with crystal violet and measuring absorbance at 595 nm (see Methods). Data are given as average ± SD 
of 2 different experiments. **P < 0.005. (C) HUVEC migration assay as above, upon expression of dominant-activated R-Ras-L61 mutant (veri-
fied by Western blotting). *P < 0.02. (D) Rnd2 expression was knocked down in HUVECs by siRNA transfection (verified by Q-PCR), and cell 
migration was assayed as above. **P < 0.005. (E) Rnd2-depleted HUVECs (same as above) were incubated with 7 nM p61-Sema3E for 4 hours, 
then fixed and stained with FITC-Phalloidin. The percentage of collapsed cells (defined as having a diameter shorter than 30 μm) is indicated on 
the graph. Data are representative of at least 3 experiments, displaying consistent results. **P < 0.005.
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not been elucidated. Notably, a common feature of guidance cues, 
including Sema3E, is their ability to act as double-faced signals. 
Here we found that Sema3E is able to independently regulate 
endothelial and tumor cells, triggering divergent functional out-
comes, through the involvement of distinctive signaling pathways. 
When we asked about the functional relevance of Sema3E signaling 
in tumor development and metastatic progression, we found that 
Sema3E endogenously expressed in tumor cells is a major determi-
nant of their invasive-metastatic behavior in vivo. Moreover, and 
relevant to the clinics, we found that Sema3E expression in human 
primary tumors correlates with their potential to form metastasis.
Sema3E had been initially identified in cancer cells; however, it 
was unclear whether its expression could impinge on tumor growth. 
We found that Sema3E overexpression reduced tumor burden in 
vivo. According to our data, this was not accounted for by direct 
suppression of tumor cell growth. In fact, the ectopic expression of 
Sema3E in different cancer cells did not inhibit their proliferation or 
survival in culture, including upon anchorage-independent growth 
in soft agar (A. Casazza and L. Tamagnone, unpublished observa-
tions). Moreover, while apoptosis was increased in Sema3E-over-
expressing tumors, the proliferation index of cancer cells was not 
significantly reduced. In fact, the tumor suppressor effect observed 
in our experiments was likely accounted for by the reduced vascular 
density induced by sustained paracrine signaling of ectopic Sema3E 
released in the tumor microenvironment, consistent with the 
endothelial repelling function observed in developmental angiogen-
esis (20). Moreover, we elucidated that the endothelial-repelling and 
inhibitory activity of Sema3E depends on the R-Ras GAP activity of 
Plexin D1 and on the expression of the regulatory molecule Rnd2. 
It is noteworthy that the potential inhibitory activity of endogenous 
Sema3E levels released by tumor cells is probably overpowered in 
vivo by proangiogenic factors in the tumor microenvironment. Con-
sistent with this hypothesis, we found that interfering with endog-
enous Sema3E expression in cancer cells did not increase tumor 
growth, while it significantly curbed metastatic spreading.
We have reported previously that Sema3E undergoes proteolytic 
cleavage by furin-like PPCs. This maturation process is strictly 
required to unleash the prometastatic activity of the semaphorin, 
Figure 6
p61-Sema3E induces tumor cell migration and invasiveness. (A) The migration of the 4 indicated tumor cell lines was assayed in Transwell 
inserts in response to purified 7 nM p61-Sema3E (included in the lower chamber). Migrated cells were quantified by staining with crystal violet 
(see Methods). Data are given as average ± SD of at least 2 different experiments and values were normalized to respective controls. *P < 0.03; 
**P < 0.005. (B) MDA-MB-435 cells transduced with p61-Sema3E or EV and subjected to Plexin D1 knockdown by RNAi (the same as in Figure 4, 
C–E). Cell migration was assessed as above, and data were normalized to EV-shRNA control. **P < 0.005. Analogous results were obtained with 
HCT-116 cells (data not shown). (C) MDA-MB-435 or A549 tumor cells were added in the upper chamber of a Transwell insert coated with Matrigel 
and allowed to invade the matrix and migrate to the lower side of the porous membrane (quantified as above). Data shown are the average ± SD 
of 2 different experiments. *P < 0.05; **P < 0.005. (D) We assessed the transmigration of p61-expressing (or control) MDA-MB-435 cells (as 
in B) through a confluent monolayer of HUVECs (see Methods for experimental details). Tumor cells were labeled with CFDA-SE before the 
experiment. Transmigrated cells were detected by a fluorescence microscope and quantified using METAMORPH software. The graph shows 
the MFI ± SD in triplicate samples. p61-Sema3E signaling enhanced the transendothelial migration of tumor cells, whereas this effect was lost 
in Plexin D1–deficient cells. ***P < 0.0005.
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since a mutated uncleavable form of full-length Sema3E has no 
prometastatic activity (19). In fact, PPCs are commonly expressed 
in tumor cell lines and human cancers, and our present data indi-
cate that the small proteolytic fragment p61 is the main form of 
Sema3E found in the conditioned media of tumor cells and in 
experimental tumor samples. Importantly, we have shown here 
that the p61 fragment is fully competent to bind the functional 
receptor Plexin D1, and it carries an endothelial cell–repelling 
activity comparable with that of the full-length molecule.
In apparent contrast with its potential inhibitory function in 
endothelial cells, p61-Sema3E enhances the inherent invasiveness 
of tumor cells and their metastatic behavior. Moreover, the recep-
tor Plexin D1 is responsible for this autocrine effect, since knock-
ing down its expression in tumor cells abates their metastatic 
potential and abrogates any proinvasive and metastatic response 
to p61. Metastasis formation is a multistep process, starting with 
tumor cell invasiveness at the primary tumor site and implicat-
ing cell migration, cell survival, and matrix degradation as well 
as the ability to overcome tissue barriers, such as vessel walls, and 
ultimately leading to colonization of distant tissues (33). In our 
study, we found that p61-Sema3E promotes tumor cell migra-
tion and invasiveness, possibly mediated by invadopodia forma-
tion. Notably, on the basis of multiple functional experiments in 
vitro (including adhesion-independent growth and survival in 
soft agar), we have ruled out that p61 may exert an antiapoptotic 
activity in tumor cells, potentially impinging on their survival in 
the blood stream (A. Casazza and L. Tamagnone, unpublished 
observations). Instead, we found that the Sema3E expression lev-
els dictate the ability of circulating cancer cells to extravasate and 
form metastatic colonies.
A few other semaphorins have been found to promote cell migra-
tion by transactivating plexin-associated tyrosine kinase receptors 
in a cell-specific manner (4–6). This suggested that an RTK could 
be similarly involved in Sema3E signaling, especially since we had 
observed Plexin D1 phosphorylation on tyrosine upon p61 stimu-
lation. Primed by the results of a phospho-proteomic screening, 
we then demonstrated that ErbB2 is the tyrosine kinase receptor 
responsible for p61-mediated signaling, leading to the invasive-
metastatic response. Notably, both the treatment with an ErbB2 
inhibitor and the selective knockdown of this RTK by RNAi result-
ed in a dramatic reduction of p61-induced tumor cell migration 
and metastatic lung colonization.
ErbB2 tyrosine kinase receptor is commonly expressed in human 
tumors, but it has no cognate ligand, and it mainly becomes acti-
vated by transphosphorylation in association with the homolo-
gous receptors EGFR or ErbB3 (30–32). We observed a minor 
increase of EGFR but not ErbB3 phosphorylation in tumor cells 
treated with p61-Sema3E, possibly suggesting that Plexin D1 sig-
nalling impinges on the activation of ErbB2-EGFR receptor het-
erodimers found in cancer cells but not in endothelial cells (see 
our preliminary data in Supplemental Figure 13, A and B). More-
over, MAPK and PLC-γ appeared to be the main signal transduc-
ers involved in the pathway, while PI3K-AKT activation was only 
marginally implicated. This is consistent with that reported in lit-
erature about the predominant involvement of PLC-γ and MAPK 
pathways downstream to ErbB2-EGFR complexes (30, 31).
It has been shown in neurons that neuropilin-1 expression levels 
can dictate differential functional responses to Sema3E in differ-
ent cell populations (26). Intriguingly, neuropilin-1 is expressed 
in HUVECs at an intermediate level between those found in the 2 
tumor cell models used in our functional experiments in vivo, i.e., 
MDA-MB-435 and A549 cells (data not shown). Moreover, p61-
Sema3E cannot interact with neuropilin-1 (data not shown). Thus, 
our data do not support the idea that neuropilin expression alone 
may account for the functional differences between Sema3E activity 
in endothelial and tumor cells. Interestingly, we found that the small 
Figure 7
p61-Sema3E enhances cancer cell metastatic extravasation. (A) MDA-MB-435 cancer cells expressing p61 (as in Figure 6) were fluorescently 
labeled and injected intravenously in nude mice. Two days later, the number of metastatic fluorescent cells was quantified in 4 lungs for each 
experimental group (at least 10 independent stereomicroscopic fields each) with METAMORPH software. Data are given as the mean of traced 
cells per field. **P < 0.005. (B) The same engineered  MDA-MB-435 cancer cells shown in Figure 6D, plus 2 additional batches of Plexin D1-
depleted cells (expressing an alternative shRNA sequence indicated by “#2”; see RT-PCR analysis on top) were fluorescently labeled and 
injected intravenously in nude mice. The number of fluorescent cells in the lungs was quantified by analyzing 4 mice for each experimental group 
(at least 10 independent stereomicroscopic fields each) with METAMORPH software. Data are given as mean of traced cells per field ± SD. The 
y-axis is in logarithmic scale. **P < 0.005.
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GTPase Rnd2, associated with Plexin D1, is required for the inhibi-
tory activity of Sema3E in endothelial cells while it is expressed at 
low levels and not implicated in Sema3E function in tumor cells (see 
Supplemental Figure 10, A and B). Conversely, tumor cells are char-
acterized by the expression of ErbB2-EGFR heterodimers, which are 
involved in Sema3E-induced invasion and metastasis.
Previously published data on the expression of Sema3E and its 
receptor in human tumors do not univocally establish a correlation 
with tumor progression. For instance, we have shown high Sema3E 
levels in mammary carcinomas (19). Moreover, others have found 
an elevated expression in high- versus low-grade glioblastomas 
(34), while the opposite was true for bladder carcinomas (35). As 
expected, the functional relevance of Sema3E as a master regulator 
of the invasive-metastatic phenotype may depend on the activity of 
additional tumor type–specific regulatory pathways as well as on 
individual genetic variability. Of note, Roodink and coworkers, in 
an immunohistochemistry analysis of nevi and melanoma samples, 
came to the puzzling conclusion that while Plexin D1 expression 
is positively correlated with tumor metastatic progression, Sema3E 
levels are regulated in the opposite manner (28). We have now ana-
lyzed a wide panel of nevi and melanoma samples, using a validated 
antibody proven to detect all isoforms of Sema3E, including p61 
(19). Our data demonstrate a significant increase of Sema3E expres-
sion in highly invasive and metastatic melanomas, compared with 
that of benign nevi and noninvasive melanomas. Notably, our data 
are further consistent with those seen in 2 independent gene expres-
sion data sets (36, 37) and support the postulated role of Sema3E 
signaling in the invasive-metastatic progression of melanomas.
We have furthermore analyzed the expression of Sema3E and 
its receptor in a wide series of colon cancer samples, for which we 
obtained detailed clinicopathological information. We found that 
while Sema3E expression is often below the detection threshold in 
Figure 8
p61-Sema3E elicits the activation of Plexin D1–associated tyrosine kinase ErbB2. (A) A549 tumor cells were starved for 48 hours and stimulated 
for 15 minutes with 7 nM p61-Sema3E or 0.2 nM Heregulin-β1 ECD (Hrg-β). ErbB2 was immunoprecipitated and analyzed by immunoblotting 
with anti–phospho-tyrosine (anti-pY) antibodies. The graph shows the average fold change of band intensity ± SD observed in 3 experiments 
(normalized to controls). (B) As above, serum-starved A549 cells were stimulated for 15 minutes with 7 nM p61 or 1 nM EGF. Then, EGFR or 
ErbB3 were immunoprecipitated using appropriate antibodies and analyzed with anti–phospho-tyrosine antibodies. (C) In analogy to the above 
experiments, ErbB2 phosphorylation in response to p61 or Hrg-β was assayed in HeLa carcinoma cells, either control or Plexin D1 depleted 
(verified by Western blot analysis). The graph shows the average fold change of band intensity ± SD observed in 3 experiments. (D) Plexin D1 
(VSV-tagged) and ErbB2, transfected into HEK293 cells, coprecipitate in a specific complex, as revealed by immunoblotting. Analogous results 
were obtained upon transfection in COS cells (data not shown). The experiment was repeated 3 times with consistent results. (E) COS cells 
transfected with VSV-tagged Plexin D1 were preincubated with either 200 nM Lapatinib, or 250 nM PHA-665752 (PHA), or vehicle, for 3 hours. 
Thereafter, cells were treated for 15 minutes with 7 nM p61 or mock stimulated. Plexin D1 was immunoprecipitated and analyzed with anti–phos-
pho-tyrosine antibodies. (F) Serum-starved A549 cancer cells, expressing endogenous Plexin D1 and ErbB2 receptors, were treated with mock 
or 7 nM p61-Sema3E for 10 minutes. Plexin D1 copurifying with ErbB2 was revealed by immunoblotting.
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nonmetastatic tumors, it is almost invariably present in primary 
tumors, giving rise to distant metastasis. Moreover, the average 
expression levels of both Sema3E and Plexin D1 were significantly 
increased in excised metastases compared with those of primary 
tumors, suggesting the acquisition of a selective advantage for 
metastatic spreading in cell-autonomous manner. This was con-
firmed upon analyzing gene expression in a subset of 8 primary 
tumors with available matched metastatic tissue from the same 
patients. In fact, the levels of both Plexin D1 and Sema3E were fur-
ther increased in the metastasis compared with the primary tumor 
in 100% and 75% of these cases, respectively (Supplemental Fig-
ure 1B). Moreover, the median expression value had a more than 
6-fold increase in metastases for both genes, and this difference 
passed statistical significance tests for Plexin D1 (P = 0.004).
Considering our data on the involvement of ErbB2 in p61-
Sema3E signaling, one would expect that metastatic human 
tumors expressing Sema3E and Plexin D1 should also contain 
ErbB2. We clearly detected ErbB2 expression in all primary colon 
carcinoma samples included in our panel (average of transcripts 
per 104 copies β-actin, 15.32 ± 2.57 ± SEM). However, there was 
no significant statistical correlation between ErbB2 expression lev-
els and the metastatic or nonmetastatic behavior of these tumors 
(data not shown). This indicates that, not unexpectedly, the ErbB2 
oncogene is not the driving force for the metastatic spreading of 
colon cancers, but it is widely expressed in tumors, consistent with 
an effector function in Sema3E–Plexin D1 signaling cascade.
We finally asked whether Sema3E expression could have any 
relevance as a predictor of clinical outcome in human cancers. 
Although providing a conclusive answer to this question is beyond 
the scope of this study, we looked carefully into our data on colon 
cancer patients. As expected, while early stage tumors (i.e., T1-T2) 
did not associate with metastasis, advanced stage colon cancers 
(i.e., T3-T4) had an overall 28% incidence of metastasis in our series 
(12 out of 43 cases). However, we noticed that among Sema3E-
Figure 9
ErbB2 kinase is required for p61-dependent promigratory and prometastatic function. (A) A549 cells were pretreated with 400 nM Lapatinib or 250 nM 
PHA-665752 for 2 hours and allowed to migrate in a Transwell insert in response to 7 nM p61-Sema3E in presence of the same inhibitors. Migrated 
cells were quantified by staining with crystal violet (see Methods). Data are given as average ± SD of 2 independent experiments. **P < 0.005. 
Analogous results were obtained by analyzing MDA-MB-435 and HeLa cancer cells (see Supplemental Figure 11, A and B). (B) A549 cells were 
transduced to establish an autocrine circuit of p61-Sema3E, fluorescence labeled with CFDA-SE, and injected systemically into mice treated with 
Lapatinib or vehicle (see Methods). Forty-eight hours after injection, metastatic fluorescent cells in the lungs were quantified (as described in Meth-
ods). The graph indicates average values ± SD of 5 mice per each experimental group. **P < 0.003. (C) The expression of ErbB2 (or Met tyrosine 
kinase as control) was knocked down in A549 tumor cells by RNAi (see Methods) and migration was assayed as above in response to 7 nM p61, 
1 nM Hrg-β, or 1 nM HGF. Data are given as average ± SD of 2 independent experiments. Statistical significance was calculated relative to mock-
treated cells in each group. *P < 0.05. (D) ErbB2-depleted A549 cells and respective controls were transduced to establish an autocrine circuit of 
p61-Sema3E (see expression analysis). Tumor cells were labeled with CFDA-SE before intravenous injection into nude mice. The graph shows 
the number of metastatic cells infiltrating the lungs after 48 hours, quantified as in B (average values ± SD of 5 mice per each experimental group). 
**P < 0.005. (E) Sema3E-induced migration of A549 cells was assayed as above, in the presence of DMSO (vehicle), or 2 μm U73122 (PLCγ), 10 μm 
PD98059 (“PD,” MAPK inhibitor), or 10 μm LY294002 (“LY,” PI3K inhibitor). PLCγ close to U73122; (MAPK inhibitor) close to PD98059, and (AKT 
inhibitor) close to LY294002. Data are given as average ± SD of 2 independent experiments. *P < 0.05, **P < 0.003.
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negative tumors the incidence of metastasis was only 10% (2 out 
of 19), whereas Sema3E-positive primary tumors had a 58% inci-
dence of metastasis (14 out of 24). Although the size of this sample 
is small, Fisher’s exact test confirmed that this is not a random 
distribution (P = 0.03), suggesting that Sema3E expression may 
predict the risk of metastatic progression in advanced tumors. To 
further assess the clinical significance of Sema3E expression in pri-
mary colorectal tumors, we analyzed a subset of patients for which 
the clinical outcome after 2 years of follow-up was known (Supple-
mental Figure 1C). Interestingly, Kaplan-Meier analysis revealed 
that Sema3E levels in primary tumors inversely correlated signifi-
cantly with patient survival. Indeed, the overall 2-year survival rate 
was 94% in patients with Sema3E-negative primary tumors but 
only 58% in patients with Sema3E-positive tumors (P = 0.02 by 
log-rank test; n = 16 for Sema3E-negative tumors and n = 12 for 
Sema3E-positive tumors). Thus, our data strongly suggest that 
Sema3E expression and signaling (via Plexin D1) correlate posi-
tively with metastatic progression and poor prognosis of human 
colon carcinomas. Moreover, taken together, our findings indicate 
Sema3E as an important “modifier” signal in cancer progression, 
potentially active in multiple human tumors.
In conclusion, we showed that Plexin D1 stimulation by p61-
Sema3E can elicit 2 independent signaling cascades and divergent 
functional effects in cancer cells and in endothelial cells. More-
over, we elucidated the functional relevance in vivo of Sema3E 
and Plexin D1 endogenously expressed in tumor cells, by showing 
that their partial knockdown is sufficient to abate the metastatic 
potential, while we ruled out that blocking endogenous Sema3E 
might promote tumor growth. We have furthermore provided sta-
tistical evidence in colon cancer patients that an elevated expres-
sion of Sema3E (and Plexin D1) strikingly increases the risk of 
metastatic progression. In sum, Sema3E autocrine signaling is 
crucially implicated to induce a metastatic behavior in multiple 
cancer cells, and it appears as a promising target for strategies 
aimed at blocking tumor metastasis.
Methods
Further information can be found in the Supplemental Methods.
Antibodies and other reagents. Myc-tagged and VSV-tagged proteins were 
detected by MoAb 9E10 (Santa Cruz Biotechnology Inc.) and P5D4 
(Sigma-Aldrich), respectively. Other antibodies were as follows: anti-mouse 
CD31 (MEC 13.3, BD Biosciences), anti–Ki-67 (DAKO), anti-activated cas-
pase-3 (Cell Signaling Technology), anti-endoglin (R&D Systems), anti-
phosphotyrosine (4G10, Upstate), biotinylated anti-human Plexin D1 (aa 
47–1271, R&D Systems), anti-ErbB2 (29D8, Cell Signaling Technology, 
and e2-4000, Invitrogen), anti-EGFR (LA22, Millipore), anti-ErbB3 (C-17, 
Santa Cruz Biotechnology Inc.), anti-Rnd2 (Proteintech Group Inc.), anti–
Caspase-9 (96.1.23, Santa Cruz Biotechnology Inc.), anti-laminB (101-B7, 
Calbiochem), anti-actin (C-11, Santa Cruz Biotechnology Inc.), anti-HA 
(Y-11, Santa Cruz Biotechnology Inc.), and anti-Vinculin (V4505, Sigma-
Aldrich). Antibodies to Sema3E were described previously (19). Recombi-
nant human Heregulin-β1 Extracellular Domain (Hrg-β) and HGF were 
from R&D Systems. Human recombinant EGF was from Sigma-Aldrich. 
Lapatinib (GW572016, Tykerb) was provided by GlaxoSmithKline or 
purchased from Sellek Chemicals. Met inhibitor PHA665752 was from 
TOCRIS Bioscience. LY294002 and PD98059 were from Calbiochem, and 
U-73122 was from Sigma-Aldrich.
Ectopic gene expression in mammalian cells. Expression constructs encoding 
full-size mouse Sema3E (fused with a polyHis-Myc-epitope tag at C’-term) 
as well as truncated p61-Sema3E (19) were subcloned into the lentiviral 
transfer plasmid pRRLsin.cPPT.hCMV.GFP.Wpre, and gene transfer was 
performed as previously described (38). This method ensured stable gene 
transfer with very high efficiency, without the need to select individual cell 
clones. In addition, we assayed multiple independent batches of cells trans-
duced with each construct. The ErbB2 mammalian expression construct 
was a gift from Thomas Diettmar (Witten/Herdecke University, Witten, 
Germany). A dominant-active R-Ras was provided by Dominique T. Brandt 
(University of Heidelberg, Heidelberg, Germany). An expression construct 
for Rnd2 was purchased from Missouri S&T cDNA Resource Center.
Purification of Sema3E molecules. COS cells were transduced to stably 
express the respective Sema3E molecules. Conditioned media were har-
vested from these cells in the absence of serum. Protein purification was 
achieved using a Nickel-loaded affinity column (GE-Pharmacia) according 
to the manufacturer’s protocols.
Knockdown of gene expression by RNAi. The expression of Plexin D1, 
Sema3E, ErbB2, and Met was silenced in tumor and/or endothelial cells 
by expressing gene-targeted shRNA. Rnd2 expression was knocked down 
in HUVECs by transfection with targeted siRNA duplexes. Details on 
reagents, procedures, and the targeted sequences are provided in the Sup-
plemental Methods.
Real-time quantitative PCR analysis of gene expression. Total RNA from tumor 
cell lines or tissues was isolated by using RNeasy Protect Mini Kit (Qia-
gen) according to the manufacturer’s instructions. cDNA preparation 
was performed according to standard procedures, using M-MLV Reverse 
Transcriptase (Promega) and oligo-dT primers (Sigma-Aldrich). Real-time 
quantitative PCR (Q-PCR) analysis was performed using the Applied Bio-
systems 7900HT Fast Real-Time PCR System and PCR primers and Taq-
Man probes listed in Supplemental Methods. Gene expression in cells 
subjected to RNAi-mediated knockdown was quantified as relative levels 
versus mock-transduced cells. On the other hand, gene expression in indi-
vidual human tumor samples was quantified as relative number of tran-
scripts compared with β-actin. Informed consent was received for human 
samples. Care and use of human samples were approved by review boards 
at the University of Heidelberg (Germany), and the Institute for Cancer 
Research and Treatment (Candiolo, Turin, Italy).
MTT cell viability assay. Transduced tumor cells were seeded in multiple 
24-well plates (5 × 104 cells/well). After 24 hours of serum starvation, the cells 
were cultured in DMEM medium containing 0.1% FBS. To reveal viability, the 
cells were incubated with 500 μl/ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) dye solution (Sigma-Aldrich) for 4 hours at 
37°C. The indicator product, formazan, was resuspended in DMSO and mea-
sured spectrophotometrically at 570 nm by a Titertek Multiskan reader.
Fluorescence labeling of living cells. MDA-MB-435 cells were incubated with 
10 μM CFDA SE Vybrant Cell Tracer (Molecular Probes) for 15 minutes 
at 37°C. Then the loading solution was replaced with fresh, prewarmed 
medium and the cultures were incubated for another 30 minutes at 37°C.
Cell migration and invasion assays. Cell motility was assayed using Transwell 
chamber inserts (Costar), with a porous polycarbonate membrane (8-μM 
pore size) as described previously (39). To allow haptotactic migration, the 
lower side of the filter was coated with 10 μg/ml fibronectin. Cells were har-
vested from culture dishes by treatment with 1 mM EDTA and resuspended 
in 0.2% BSA-containing medium. Approximately 1 × 105 cells were added in 
the upper chamber and allowed to migrate through the filter toward the 
lower chamber (including regulatory molecules, when indicated) for 6–8 
hours in a cell culture incubator. Then, the cells adherent to the upper side 
of the filter were mechanically removed, while those that migrated to the 
lower side of the filter were fixed with 11% glutaraldehyde and stained with 
crystal violet. The dye was then solubilized in 10% acetic acid to measure 
absorbance at 595 nm in a microplate reader (OD values are shown in the 
graphs as arbitrary units). For ECM invasion assays, 5 × 105 tumor cells 
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were added to the upper chamber of a Transwell insert coated with Matrigel 
(20 μg/well; Becton Dickinson) and allowed to migrate in 1% FBS-contain-
ing medium. After 16 hours of incubation, the cells adherent to the lower 
side of the porous membrane were fixed and analyzed as above.
Transendothelial migration of tumor cells. Approximately 1 × 105 HUVECs 
were added to type I collagen-coated 24-well Transwell inserts with small 
pore sizes (5-μm pore size; Costar) and grown to confluence for 3 days, 
with daily replacement of fresh culture medium, until they formed a tight-
ly packed monolayer. Then, 7 × 105 CFDA-SE–labeled (see above) MDA-
MB-435 cells, resuspended in HUVEC culture medium, were added to the 
upper chamber. After incubation for 16 hours, the cells were fixed with 11% 
glutaraldehyde, and the upper side of the membranes were gently scraped 
with a cotton swab to remove nonmigrated cells. Transmigrated tumor 
cells were quantified based on green fluorescence in 5 random fields, using 
METAMORPH software.
Animal model and in vivo procedures. In vivo studies were conducted in 6- to 
8-week-old immunocompromised Cd1–/– nude athymic or BALB/C female 
mice (Charles River Laboratory). Unless otherwise indicated, in each exper-
iment, we analyzed 6 tumors per each condition. For subcutaneous tumor 
models, 2 × 106 MDA-MB-435, 8 × 106 A549, or 5 × 105 4T1 cells were 
injected into the right posterior flank of anesthetized animals. Tumor size 
was measured externally every 2 days using a caliper, and tumor volume 
was estimated using the equation V = 4/3p × (d/2)2 × D/2, where d indicates 
the minor tumor axis, D indicates the major tumor axis, and V indicates 
volume. Mice were sacrificed after 30–60 days after transplant, and tumors 
were weighted after dissection. Superficial pulmonary metastases were 
contrasted using black India ink to infuse airways, and counted on dis-
sected lung lobes under a stereoscopic microscope. For orthotopic injec-
tion, 1 × 106 4T1 cells resuspended in 40 μl phosphate-buffered saline were 
injected into the second mammary fat pad of anesthetized Balb/c mice, fol-
lowing exposure by a small incision. Mice were sacrificed after 25 days, and 
tumors and lungs were measured as mentioned above. For experimental 
metastasis assays, 2 × 106 MDA-MB-435, 6 × 106 A549, or 2 × 105 4T1 cells 
were injected into the lateral mouse tail vein; for long-term experiments, 
cell colonies were scored in the lung using black India ink to infuse airways, 
as described above. Short-term metastatic extravasation of fluorescent can-
cer cells in the lungs was quantified by analyzing 4 pairs of lungs for each 
experimental group (at least 10 independent microscopic fields each) with 
METAMORPH software. For experiments based on in vivo Lapatinib treat-
ments, mice received the vehicle (0.5% hydroxypropylmethylcellulose with 
0.1% Tween 80 in water) or the drug (100 mg/kg body weight) daily by oral 
gavage, from 3 days before to 2 days after systemic tumor cell injection. 
Animal procedures had been approved by the Ethical Commission of the 
University of Torino and by the Italian Ministry of Health.
Histological analysis. Paraffin-embedded or OCT-embedded frozen sam-
ples were cut in 10-μm thick sections and probed with primary antibodies 
(listed above). Streptavidin was conjugated with HRP (DAKO), while all 
secondary antibodies used were conjugated with Alexa Fluor 488 or Alexa 
Fluor 546 fluorochromes (Molecular Probes). To detect apoptotic cells 
in tumor sections, we used an indirect TUNEL assay, using the ApopTag 
Green In Situ Apoptosis Detection Kit (Chemicon). Slides were analyzed 
using a Leica DM IRBM microscope, and digital images were evaluated 
with METAMORPH software. Unless otherwise indicated, quantification 
was done by analyzing at least 3 sections and 10 fields per tumor (consider-
ing 6 tumors per experimental condition).
Immunoprecipitation, SDS-PAGE, and Western immunoblotting. Cellular pro-
teins were analyzed using standard methods, as described in the Supple-
mental Methods, using antibodies listed above. Band intensity quantifica-
tion was done with Quantity-One software.
Statistics. Statistical significance was verified using the 2-tailed Student’s 
t test. P values of less than 0.05 were considered significant.
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